Related Experiment Video
Updated: May 25, 2026

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria
Published on: February 23, 2014
[Study of hospitalizations for pneumococcal pneumoniae in Centre region, 2004-2008]
L Grammatico-Guillon1, N Thiercelin, S Mariani
1Service d'information médicale, d'épidémiologie et d'économie de la santé, hôpital Bretonneau, CHRU de Tours, 2, boulevard Tonnelé, 37000 Tours, France. leslie.guillon@univ-tours.fr
Insights
Pneumococcal pneumonia hospitalizations in France show a significant burden, with low vaccine coverage highlighting a need for improved public health strategies. This study analyzed regional data to understand disease impact and inform vaccination campaigns.
Area of Science:
- Infectious Diseases
- Epidemiology
- Public Health
Context:
- Streptococcus pneumoniae is a leading cause of pneumonia and infectious disease deaths in France.
- Vaccines exist for children and adults to prevent severe pneumococcal illness.
- Hospitalization data from the Centre region (2004-2008) was analyzed to assess pneumococcal pneumonia burden.
Purpose:
- To analyze hospitalizations for pneumococcal pneumonia in France's Centre region between 2004 and 2008.
- To determine the clinical impact, patient demographics, and vaccine coverage associated with pneumococcal pneumonia.
- To evaluate the utility of national hospital discharge databases for epidemiological studies.
Summary:
- 1,541 hospitalizations for pneumococcal pneumonia were identified in the Centre region from 2004-2008.
- The study found a median patient age of 58, a male-to-female ratio of 1.43, and significant hospital impact including ICU stays (20%) and a 6% mortality rate.
- Vaccine coverage among hospitalized patients was only 23%.
Impact:
- The study highlights the substantial clinical impact of pneumococcal pneumonia in the region, consistent with national trends.
- National hospital discharge databases can serve as valuable epidemiological tools, despite potential biases.
- Findings support the organization of regional vaccination campaigns to improve pneumococcal disease prevention.
Background:
Streptococcus pneumoniae is a significant cause of morbidity-mortality: leading agent of community-acquired pneumonia and the first cause of death due to infectious diseases in France. Vaccines are available for children and adults, avoiding serious complications. We studied hospitalizations for pneumococcal pneumonia in Centre region in 2004-2008, using the 2004-2008 national hospital discharges database and assessed vaccine coverage of a sample population.
Methods:
Hospital discharges with diagnosis of pneumococcal pneumonia were selected, using the corresponding code (J13) in the French Diagnosis-Related Group coding system. We analysed hospitalization and patient data using linkage of the inpatient stays with their anonymous identification number. We analysed hospitalization and patient data: number and length of stay/patient, co-morbid factors and pneumococcal immunisation status.
Results:
One thousand five hundred and forty-one hospitalisations were found for pneumococcal pneumonia in Centre Region, in 2004-2008. The time pattern showed an annual increase in hospital stays: winter hospitalisations were most frequent. The median age was 58 years, range: 2 months-106 years. The sex ratio M/F of the 1417 distinct inpatients was 1.43. The hospital impact was substantial, with prolonged length of stay (mean=9.9 days), frequent stays in intensive care unit (20%) and high death rate (6%). The vaccine coverage of the population with pneumococcal pneumonia was only 23%.
Conclusion:
Using the national hospital discharges database, this study presents a snapshot of pneumococcal pneumonia in one French region and demonstrates the local major clinical impact, as found in France. It shows that the hospital discharge database is a potential tool for epidemiology despite its possible bias. This type of study could be useful for organizing a regional vaccination campaing due to the better knowledge of the disease.
Related Concept Videos
Pneumonia I: Introduction
Pneumonia I: Introduction
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Pneumonia III: Complications and Assessment
Pneumonia V: Nursing management and Prevention
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed.
Pneumonia II: Pathophysiology

